Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

JasonZemanskyPhD May. 11 at 1:50 AM

$ESPR good that now bulls and bears don’t have to predict a thing

0 · Reply

Enjoyycall May. 11 at 1:39 AM

$ESPR

0 · Reply

MrPeter May. 11 at 12:03 AM

$ESPR I hope Sheldon’s mom said she is very ashamed of him today.

2 · Reply

rsdev May. 10 at 11:41 PM

$ESPR Happy Mother's Day to all the wonderful Moms out there. Just wanted to see what others thinking is regarding the due diligence being done (or already done) by any of the BPs out there. My presumption is that these BPs know much more than us in validating the viability of any of their bids to acquire successful companies. That said, if we don't see any counter bids for ESPR in the next few weeks, does that really mean the existing offer by Archimed is all that is deserved by ESPR?

1 · Reply

Gregg617 May. 10 at 7:02 PM

$ESPR Happy Mother’s Day to Minnesota and the rest of the moms

0 · Reply

meistermell May. 10 at 6:03 PM

$ESPR no need to argue, Q1 was a good quarter. In accounting you can make good quarters look bad and put lipstick on bad quarters. Every Q1 deductibles reset and if there is strong patient demand you will need to subsidize more, Q2 is going to be a monster, script (Q1 ~9%, Q2 ~20% groth) and revenue wise. DSE is having record quarter after record quarter, total revenues soon to be over 100MM per Q without milestones. 2027 total revenues lilely in the 500MM-1billion range (incl. milestones). We'll see if a topping bid matures

1 · Reply

BBRC May. 10 at 5:44 PM

$ESPR I have traded in and out of this stock since the inception way back when. Two years ago I did extensive research before taking a long-term position. One of the best articles I came across was a written by you on another site... you were bullish at that point... the research in that article helped firm my decision to take a long-term position here. Even if the sale closes at this lowball offer i have doubled my money because i bought at the right time. Much respect to you and your article.

0 · Reply

BBRC May. 10 at 4:59 PM

$ESPR There is no crying in baseball or stock trading. But facts matter. Why would I cry? I have doubled my money 4 separate times on this stock. Is management weak... yes... but this is a biotech and not Apple... weak management is part of the price you pay to play in this space. I sold $1.50 Dec 26 puts... the price went from $.35 to $.05 when they announced the sale... i am not crying! But i am holding all my long term shares... looking for a higher bid or to collect my share of the legal settlements that most certainly come if the deal closes as priced.

0 · Reply

__LucidDreamer__ May. 10 at 4:40 PM

$ESPR doesnt matter if it cant translate to sales! Stop trying so hard. Mgmt trashed this.

0 · Reply

BBRC May. 10 at 3:44 PM

$ESPR US demand remained strong in Q1. Script growth was +9% for the weakest quarter of thr year.

1 · Reply

Esperion downgraded to Hold from Buy at Needham

2026-05-01T19:26:03.000Z - 9 days ago

Esperion downgraded to Hold from Buy at Jefferies

2026-05-01T18:06:50.000Z - 9 days ago

Esperion downgraded to Neutral from Overweight at Piper Sandler

2026-05-01T15:12:52.000Z - 9 days ago

Esperion downgraded to Neutral from Buy at H.C. Wainwright

2026-05-01T12:46:24.000Z - 9 days ago

Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald

May 1, 2026, 7:37 AM EDT - 9 days ago

Archimed to take Esperion Therapeutics private in $1.1 billion deal

2026-05-01T11:17:53.000Z - 9 days ago

Esperion to be acquired by Archimed for $3.16 per share, one CVR

May 1, 2026, 7:00 AM EDT - 9 days ago

Esperion to be Acquired by ARCHIMED

Apr 23, 2026, 8:00 AM EDT - 17 days ago

Esperion to Report First Quarter 2026 Financial Results on May 7

Apr 13, 2026, 9:30 AM EDT - 27 days ago

Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-02T20:16:16.000Z - 5 weeks ago

Esperion, Athyrium Capital enter $50M royalty financing agreement

Apr 2, 2026, 4:05 PM EDT - 5 weeks ago

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Apr 2, 2026, 4:00 PM EDT - 5 weeks ago

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

2026-03-30T13:21:46.000Z - 5 weeks ago

Esperion showcases new data from CLEAR Outcomes trial

2026-03-16T10:51:45.000Z - 7 weeks ago

Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline

Mar 16, 2026, 6:30 AM EDT - 7 weeks ago

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

2026-03-13T09:36:20.000Z - 2 months ago

Esperion price target raised to $5 from $4 at Citizens

Mar 11, 2026, 8:25 AM EDT - 2 months ago

Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026

2026-03-10T12:06:41.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 10, 2026

AVAV BNTX FNV GRPN KSS NIO ORCL

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Earnings Call Transcript: Q4 2025

2026-03-10T10:06:52.000Z - 2 months ago

Esperion reports Q4 EPS 22c, consensus 28c

2026-03-10T10:06:13.000Z - 2 months ago

Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025

Mar 10, 2026, 6:00 AM EDT - 2 months ago

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 3, 2026, 8:00 AM EST - 2 months ago

Esperion Therapeutics Transcript: M&A announcement

2026-03-03T11:05:38.000Z - 2 months ago

Esperion signs definitive acquisition of Corstasis Therapeutics

Mar 3, 2026, 6:00 AM EST - 2 months ago

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Feb 18, 2026, 8:00 AM EST - 2 months ago

Esperion to Participate in The 2026 Citizens Life Sciences Conference

2026-02-17T13:16:28.000Z - 2 months ago

Esperion reaches settlement agreement with Alkem

Feb 17, 2026, 8:00 AM EST - 2 months ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Feb 11, 2026, 4:30 PM EST - 3 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 14, 2026, 5:15 PM EST - 4 months ago

Esperion Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T00:25:16.000Z - 4 months ago

Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M

Jan 11, 2026, 6:00 PM EST - 4 months ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

2025-12-19T13:16:23.000Z - 5 months ago

Esperion’s bempedoic acid receives recommendation in 2025 ACC statement

Dec 3, 2025, 3:30 PM EST - 5 months ago

Esperion Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 7:00 AM EST - 6 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 18, 2025, 3:00 AM EST - 6 months ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 2:00 PM EST - 6 months ago

Esperion Therapeutics Transcript: KOL Event

Nov 6, 2025, 8:00 AM EST - 6 months ago

Esperion Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 6 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Oct 27, 2025, 8:00 AM EDT - 6 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 7, 2025, 9:29 PM EDT - 7 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 7 months ago

Esperion Announces Proposed Public Offering of Common Stock

Oct 3, 2025, 8:00 AM EDT - 7 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Sep 19, 2025, 8:00 AM EDT - 8 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 8, 2025, 2:00 PM EDT - 8 months ago

Esperion Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:45 AM EDT - 8 months ago

Esperion Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 8:00 AM EDT - 9 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 5, 2025, 8:00 AM EDT - 9 months ago

Esperion Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 9 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 10 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 11 months ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 9, 2025, 10:40 AM EDT - 11 months ago

Esperion Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 1:25 PM EDT - 1 year ago

Esperion Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 10:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:30 PM EDT - 1 year ago

Esperion Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 6:30 AM EDT - 1 year ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Status Update

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 7, 2025, 8:45 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: KOL Event

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 5, 2024, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 11:30 AM EST - 1 year ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 1 year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 19, 2024, 10:55 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2024, 10:55 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jul 16, 2024, 8:00 AM EDT - 1 year ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Jun 28, 2024, 7:00 AM EDT - 2 years ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

Jun 12, 2024, 8:40 AM EDT - 2 years ago

Esperion Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 4:30 PM EDT - 2 years ago

Esperion Therapeutics Transcript: Jefferies Global Healthcare Conference

May 23, 2024, 9:00 AM EDT - 2 years ago

Esperion to Participate in Upcoming June Investor Conferences

JasonZemanskyPhD May. 11 at 1:50 AM

$ESPR good that now bulls and bears don’t have to predict a thing

0 · Reply

Enjoyycall May. 11 at 1:39 AM

$ESPR

0 · Reply

MrPeter May. 11 at 12:03 AM

$ESPR I hope Sheldon’s mom said she is very ashamed of him today.

2 · Reply

rsdev May. 10 at 11:41 PM

1 · Reply

Gregg617 May. 10 at 7:02 PM

$ESPR Happy Mother’s Day to Minnesota and the rest of the moms

0 · Reply

meistermell May. 10 at 6:03 PM

1 · Reply

BBRC May. 10 at 5:44 PM

0 · Reply

BBRC May. 10 at 4:59 PM

0 · Reply

__LucidDreamer__ May. 10 at 4:40 PM

$ESPR doesnt matter if it cant translate to sales! Stop trying so hard. Mgmt trashed this.

0 · Reply

BBRC May. 10 at 3:44 PM

$ESPR US demand remained strong in Q1. Script growth was +9% for the weakest quarter of thr year.

1 · Reply

MoEndo May. 10 at 1:23 PM

$ESPR lot of jobs posted over the last week. Nothing like flipping the switch after signing on the dotted line to steal the company right when scripts inflect. More evidence of manipulation.

0 · Reply

__LucidDreamer__ May. 10 at 1:10 PM

$ESPR @Dave_100 is my info correct? They were down q/q? That is horrible if true. We probably would have sunk to $1.50 if they had an ER and there was no buyout announced yet. Revenue (NEXLETOL/NEXLIZET) • Q1 2026: $43.4 million • Q4 2025: $43.7 million • Q3 2025: $40.7 million • Q2 2025: $40.3 million • Q1 2025: $34.9 million • Q4 2024: $31.6 million • Q3 2024: $31.1 million • Q2 2024: $28.3 million • Q1 2024: $24.8 million This mgmt was truly horrid and inept. And yes, BA still costs over $100/mo on my major insurance thru expressscripts. Probably why they kept giving out discounts. Dumbass Believer probably still touting a Tolvaptin partnership announcement any day now. With Foody doing the presser!

1 · Reply

NEXLIZET_REALWORLD_STUDY May. 10 at 5:07 AM

$ESPR Big Pharma could easily make billions off Bempedoic acid

1 · Reply

Georges8792 May. 10 at 4:45 AM

$ESPR they should have added a CVR of 1 USD on the positive outcome of the Sandoz trial

1 · Reply

Enjoyycall May. 10 at 4:35 AM

$ESPR Just took my dog for a walk at the northern lare and she took a omar. She usually omar’s in the same spot.

1 · Reply

Enjoyycall May. 9 at 11:45 PM

$ESPR how much do need me to pump guts to save you gas money?

1 · Reply

JasonZemanskyPhD May. 9 at 11:39 PM

$ESPR it’s fun to see, how everyone who were bulish and avoided all the red flags 🚩 suddenly blaming Sheldon , Ben, market, etc etc but self

2 · Reply

Enjoyycall May. 9 at 10:37 PM

$ESPR

1 · Reply

MoEndo May. 9 at 10:04 PM

$ESPR they must have purposefully delayed the tech transfer to allow for the stacking of inventory. I hope that any and all of these attorneys are able to easily sift through the BS and hang these guys out to dry. This has been pure manipulation for at least two years and likely the plot was in the works far before, but they needed cover of the NDA. Absolutely criminal. I think and hope there is a bid, otherwise I’m in it for the lawsuit and I doubt it will be a 17 million dollar settlement like Portola.

0 · Reply

TripleWitch May. 9 at 8:54 PM

$ESPR NAMS value at $4.5 billion while $ESPR and FDA approved Bempedoic Acid bought for $1.1 billion? Bullshit CRIMINAL buyout at $3.16…. 🔥 🗑️ 🔥

0 · Reply

Bear0927 May. 9 at 8:43 PM

$ESPR That Vanguard nonsense is resolved. They have an additional 2M shares on top of their old position in the newest 13s filed. Fintel at 70% institutional ownership

0 · Reply

perchedcats May. 9 at 7:16 PM

$ESPR it’s like sheldon anf archimed made sure to get the BO in before s riots and revenue exploded. what a bunch shameless corrupt crooks - both of them. It takes two to tango

0 · Reply

Market Cap	808.25M
Revenue (ttm)	403.14M
Net Income (ttm)	-22.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	68.26
Profit Margin	-5.63%
Debt to Equity Ratio	-0.50

Volume	7,428,000
Avg Vol	11,703,988
Day's Range	N/A - N/A
Shares Out	257.41M
Stochastic %K	97%
Beta	0.91
Analysts	Hold
Price Target	$2.91